Document is current

Article History

Received: 28 October 2021

Revised: 13 January 2022

Accepted: 13 January 2022

First Online: 11 February 2022

Declarations

:

: Yasutaka Ueda received support from Alexion in relation to this study; and has received consulting fees from Alexion, Sanofi, Chugai, and Novartis, honoraria/lecture fees from Alexion Pharma, Sanofi, and Novartis, and participation on data safety monitoring boards or advisory boards for Novartis and Sanofi, unrelated to this study. Kensuke Usuki has received research grants from Astellas, AbbVie, Apellis, SymBio, Daiichi-Sankyo, Novartis, Janssen, Otsuka, Astellas-Amgen-Biopharma, Takeda, Nippon Shinyaku, Bristol-Myers-Squibb, Amgen, Alexion, Incyte, Ono, Kyowa-Kirin, Celgene, Sumitomo-Dainippon, Chugai, Pfizer, Mundi, Yakult, MSD, Gilead, and Nippon-Boehringer-Ingelheim and honoraria/lecture fees from Novartis, Bristol-Myers-Squibb, Sanofi, Pfizer, AbbVie, Takeda, Ono, Kyowa-Kirin, Astellas, Alexion, Eisai, MSD, Otsuka, Celgene, Daiichi-Sankyo, Nippon Shinyaku, PharmaEssentia, Yakult, SymBio, Alexion, and Chugai, unrelated to this study. Takahisa Matsuda, Hirozumi Akiyama, and Akihiko Shimono are employees of and hold stock in Alexion. Yuji Yonemura and Tatsuya Kawaguchi have received honoraria/lecture fees from Alexion unrelated to this study. Shigeru Chiba has received honoraria from Janssen, Eisai, Sanofi, Sumitomo-Dainippon, Kyowa-Kirin, Chugai, CSL Bering, Nippon Shinyaku, Meiji-Seika, Novartis, Bristol-Myers-Squib, Astellas, and Otsuka, unrelated to this study. Jun‑ichi Nishimura has received consulting fees from Alexion, Roche, Chugai, Novartis, Apellis, BioCryst, and Sanofi, and has patents issued or pending with Roche and Chugai, unrelated to this study. The other authors have no conflicts of interest to declare.